"Hemispherx is thus being penalized for the scientific community's willful ignorance on CFS for decades, and not being rewarded for taking a major risk of pushing Ampligen through clinical trials."
Actually, if you'll read the FDA document that was released yesterday, it's clear that the exact opposite it true.
Hemispherx refused to comply to the FDA's 2009 request for a new, larger and longer trial, and instead manipulated the results from two earlier trials. They're pissed at the way the Hemispherx may have withheld information about adverse effects, removed like 20 or so patients from the original analysis to make the outcomes look better, etc..
If it isn't approved, I wouldn't blame the FDA, but instead ask Hemispherx why they didn't comply with the FDA's 2009 requests? Hopefully they'll be asked these questions tomorrow.
Here's a link to the FDA's analysis -- it doesn't look good at all -- and although this document is like 600 pages, just reading and skimming from about page 15 to page 30 will make it clear that they're not pleased with Hemispherx at all.
http://www.fda.gov/downloads/Adviso...rugs/ArthritisAdvisoryCommittee/UCM332514.pdf